Minimal Change in CAR T Cell Manufacturing Can Impact in Expansion and Side Effect of the CAR T Cell Therapy

• Published in: Blood Vol. 132; no. Supplement 1; p. 4012
• Main Authors: Ceppi, Francesco, Annesley, Colleen, Finney, Olivia, Summers, Corinne, Rhea, Stephanie, Jenkins, Isaac C., Wu, Qian V., Yang, Wen, Pulsipher, Michael A., Wayne, Alan S., Park, Julie R., Gardner, Rebecca, Jensen, Michael C.
• Format: Journal Article
• Language: English
• Published: Elsevier Inc 29.11.2018

Introduction: Chimeric antigen receptor (CAR)-modified T cells targeting CD19 can induce potent and sustained responses in children with relapsed/refractory acute lymphoblastic leukemia (rrALL). We previously reported a robust intent-to-treat product-manufacturing success rate of 100% in minimally s...